19.10.2022: Antimicrobial resistance (AMR) presents a significant challenge for cancer patients, with 1 in 5 requiring hospitalisation due to infection. Antibiotics remain a crucial part of cancer care, but resistance is growing and the development pipeline is waning. We need immediate and co-ordinated action now to secure better outcomes for cancer patients.
A new collection of articles published by AMR Control in partnership with the Union for International Cancer Control (UICC) explore the challenges AMR presents for cancer patients, with contributions from over 50 subject experts.
“Without viable antibiotics to prevent and treat infections, key advances made in the care and treatment of cancer patients will be limited due to the risks of severe infections”
Read the Global AMR R&D Hub’s contribution in collaboration with Dr. Stefan Schwartz from Charité – Universitätsmedizin Berlin here.
Access the full supplement here
Contact for further information:
Dr. Lesley Ogilvie
Email: globalamrhub@dzif.de
